【摘要】 目的：评估术前1wk玻璃体腔内注射贝伐单抗对增生性糖尿病视网膜病变(PDR)玻璃体手术(PPV)的效果。方法：对46例PDR患者进行回顾性研究，46例患者随机分为玻璃体手术(PPV)组(n=28)和IVB组(n=18, PPV术前注射贝伐单抗)。玻璃体术前1wk注射贝伐单抗，比较两组间视力，医源性视网膜裂孔发生率，术中和术后出血情况。结果：术后1mo，PPV组和IVB组视力都明显提高(82.1%对88.9%)(P<0.01)，两组间并无明显差异。医源性视网膜裂孔发生率PPV组18例，IVB组4例(64.3%对22.2%)(P<0.05)。术中出血PPV组28例，IVB组7例(100%对39%)(P<0.01)，术后出血PPV组9例，IVB组0例(32.1%对0)(P<0.01)。结论：术前注射贝伐单抗可以减少增生性糖尿病视网膜病变玻璃体手术中医源性视网膜裂孔、术中出血和术后出血发生率。
【关键词】 贝伐单抗;血管内皮细胞生长因子;增生性糖尿病视网膜病变;玻璃体切除手术
INTRODUCTION
Nonclearing vitreous haemorrhage, preretinal fibrovascular membrane and tractional retinal detachment are major causes of severe vision decrease in patients with proliferative diabetic retinopathy (PDR)[1]. Vitrectomy is generally used to remove vitreous haemorrhage and preretinal fibrovascular membranes and relief of vitreoretinal traction. Intraoperative bleeding and iatrogenic retinal breaks were the main complications during surgery of removing preretinal fibrovascular membrane in PDR[2]. Intraoperative bleeding interferes with fundus examination, detection of iatrogenic retinal breaks, performing laser therapy and leads to timeconsuming surgery. Ghost cell glaucoma and postoperative bleeding are main consequences of this complication[3].
Bevacizumab (Avastin), a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) was approved by the US Food and Drug Administration (FDA) for the treatment for metastatic colorectal cancer. Recent reports on the intravitreal bevacizumab (IVB) injection showed promise for targeting VEGFimplicated intraocular neovascularization seen in agerelated macular degeneration and proliferative diabetic retinopathy (PDR)[4]. It has been recently shown to enhance the clearance of vitreous hemorrhage and induce involution of retinal neovascularization and anterior segment neovascularization with no reported complications and has been used in the treatment of proliferative diabetic retinopathy (PDR) and other retinal vascular diseases[4,5]. The purpose of this study is to evaluate the effect of intravitreal bevacizumab (IVB) injection before vitrectomy in PDR patients.
MATERIALS AND METHODS
Participants and Grouping Preoperative evaluation included blood hypertension, blood glucose, bestcorrected visual acuity (BCVA), slitlamp, gonioscopy, ultrasonography and fundus fluorescein angiography (FFA). The surgical indication included preretinal fibrovascular membrane involving or threatening the macula, unclearing vitreous hemorrhage of at least 1 month, vitreous hemorrhage with rubeosis iridis, massive preretinal bleeding covering the posterior pole and BCVA of 0.12 or worse. Patients with pregnancy, history of haemodialysis, history of IVB injection and vitrectomy, BCVA of 0.15 or better were excluded.
Fortysix PDR patients undergoing pars plana vitrectomy (PPV) were divided into 2 groups; PPV group (28 patients, 28 eyes) undergoing PPV from Jan. 2006 to Jun. 2008 and IVB group (18 patients, 18 eyes) undergoing PPV with preoperative IVB injection from July 2008 to Jun. 2009. The age of the patients in PPV group ranged between 34 and 60 years with a mean of 43±12 years; 12 patients (42.9%) were male and 16 (57.1%) were female. The age of the patients in IVB group ranged between 36 and 58 years with a mean of 42±9 years; 10 patients (55.6%) were male and 8(44.4%) were female. BCVA of all cases was less than 0.12. All cases had type 2 diabetes mellitus and had not previous panretinal photocoagulation(PRP) treatment.
This study was approved by the local research committee. All patients signed a consent form before the study.
Surgical Interventions Bevacizumab was injected 7 days prior to surgery. 1.5mg(0.06mL) of bevacizumab(100mg/4mL; Genentech, South San Francisco, California) was injected into the vitreous cavity using a 26gauge needle, 3.54mm posterior to the inferotemporal limbus after topical anaesthetic administration under sterile conditions.
Standard 3port pars plana vitrectomy (PPV) using 20G vitrectomy systems (Bausch & Lomb, USA). Preretinal fibrovascular membranes were removed using different techniques including membrane peeling, segmentation, delamination and en bloc dissection. PRP was done at the end of surgery. No internal limiting membrane peeling was done in any of the surgeries. The internal tamponade used was decided intraoperatively, either air or silicone oil (silicone oil was used if any multiple retinal break occurred during fibrovascular tissue dissection).
Patients were examined after 1 day, 1 week, and 1 month postsurgery.
Statistical Analysis Values were expressed as mean±standard deviation. Software used was SPSS 10.0. P<0.05 was considered statistically significant.
RESULTS
PPV Group Bestcorrected visual acuity of 1 month after surgery showed improvement in 23 cases (82.1%), stabilized in 1 cases (3.6%) and deteriorated in 4 eye (14.3%). The mean final visual acuity reached 0.12. Six cases (21.4%) reached 0.5 or better.
Intraoperative bleeding was encountered in all cases. Iatrogenic retinal breaks were reported in 18 cases (64.3%). Gas was used in 3 cases (10.7%) and silicone oil in 15 cases (53.6%). Postoperative bleeding was reported in 9 eyes (32.1%); 3 cases of them were during the first one postoperative week and 1 occurred 1 month after PPV. Seven cases cleared spontaneously within 13 weeks without treatment and 1 case was performed repeat surgery.
IVB Group Final visual acuity showed improvement in 16 cases (88.9%), no change in 2 cases (11.1%). The mean final visual acuity reached 0.15. Eight cases (44.4%) reached 0.5 or better. The difference in the mean visual acuity between the two groups was not statistically significant (P>0.05).
Intraocular bleeding was encountered in 7 cases (100% in PPV group and 39% in IVB group, P<0.01). Iatrogenic breaks occurred in 4 cases (64.3% in PPV group and 22.2% in IVB group, P<0.05). Silicone oil was used in these 4 cases (22.2%). Postoperative bleeding was reported none in IVB group (32.1% in PPV group and 0 in IVB group,P<0.01).
[1] [2] 下一页 |
